Expertise and resources to facilitate
Preclinical characterization of oncology nanomedicines
Expediting nanomedicine development
Protocols

Nanotechnology Characterization Lab

Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.

The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.

Learn about how to collaborate with the NCL.

News & Updates

The NCL has recently published a review article entitled “Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer” in Nature Reviews Clinical...

NCL’s Sr. Principal Scientist in Pharmacology & Toxicology, Dr. Stephan Stern, has spearheaded several important publications on the complexity of nanomedicine...

The NCL recently hosted its 8th edition of the popular Lessons Learned Workshop (LLW) seminar series. This year’s meeting was condensed into an intensive half-day series of...

Meet Us @

The 2017 International Advanced Drug Delivery Symposium (IADDS) will be held in Taipei, Taiwan, April 6-7, 2017. NCL’s Sr. Principal Scientist in Immunology will be speaking....

NCL’s Director, Scott McNeil will be speaking at the 2017 FIP Pharmaceutical Sciences World Congress (PSWC) in Stockholm, Sweden. Additional details will be posted as soon as...